Precision treatment advances cancer care with new noninvasive technology

Wellstar MCG Health and the Georgia Cancer Center at Augusta University have begun treating patients using the new Elekta Esprit Gamma Knife, the latest state-of-the-art system for noninvasive treatment of neurological and oncologic conditions. The new technology provides patients with the gold standard for non-invasive brain tumor and cancer treatments, underscoring Wellstar and the Georgia Cancer Center’s dedication to innovation and patient-centered care.

The Gamma Knife Esprit delivers highly precise radiation therapy – to within 0.15 mm accuracy – which allows physicians to better treat complex or previously inoperable conditions while preserving surrounding healthy brain matter without the need for traditional surgery. This advanced technology minimizes risk, reduces recovery times and offers hope to patients who may not be candidates for more traditional procedures.

“Bringing the Gamma Knife Esprit to Augusta and the CSRA represents a transformative leap in neurosurgical care for our region,” said Fernando Vale, MD chair of the Department of Neurosurgery at Wellstar MCG Health and the Medical College of Georgia at Augusta University. “With its pinpoint accuracy and utmost precision, we can treat many complex neurological conditions. This incisionless technique can help us manage many illnesses of the brain including facial pain and very difficult brain tumors while preserving quality of life and reducing patient discomfort.”

Gamma Knife Esprit can target the smallest tumors and lesions with sub-millimeter precision – smaller than the size of a pencil tip – to treat brain lesions, tumors and vascular abnormalities without incisions or general anesthesia. This non-invasive approach results in shorter hospital stays, fewer side effects and faster recovery, making it a powerful resource for patients and their families.

John Barrett, MD, chair of the Department of Radiation Oncology at MCG, added, “This technology allows us to provide effective, non-invasive treatment options for patients with brain tumors, vascular malformations and other neurological disorders. It’s a significant step forward for our patients and our clinical teams.”

“It is a privilege to serve our community by bringing leading-edge care to the CSRA,” said Ralph Turner, president of Wellstar MCG Health. “This cutting-edge technology strengthens our Neuroscience Center of Excellence and the Georgia Cancer Center, but most importantly, it ensures that patients from across the region have access to world-class, noninvasive treatment options close to home.”

The addition of the Gamma Knife Esprit further reinforces Wellstar MCG Health’s position as a leader in advanced neurological and cancer care. Through continued investment in technology and partnerships, Wellstar MCG Health remains committed to excellence, innovation and the well-being of every patient it serves.